This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Genzyme Recognizes Sixth Annual World MS Day

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today recognizes World MS Day, an initiative developed by the Multiple Sclerosis International Federation (MSIF) to raise awareness of MS and its impact on the lives of more than two million people around the world. With two differentiated MS therapies and a research pipeline focused on innovative approaches to treating the disease, Genzyme has a long-term commitment to the MS community.

“World MS Day recognizes the significance of MS on a global scale, and it’s an important reminder of the challenges faced by everyone affected by this devastating disease,” said Bill Sibold, Genzyme’s Senior Vice President and Head of MS. “We’re inspired every day by people living MS and the people who care for them, and we’re constantly pushing ourselves to transform what it means to receive an MS diagnosis.”

Genzyme sites around the world are partnering with local patient organizations on a variety of World MS Day activities. Genzyme supports people living with MS through grants and partnerships intended to address a range of unmet needs. This year, the company has provided funding to more than 70 organizations in support of more than 200 patient advocacy projects. Key 2014 grants and partnerships include:

Shift.ms: Genzyme is partnering with this social network, which is focused on reducing isolation and increasing support for people living with MS. The company is sponsoring efforts by Shift.ms to gather information from people with MS in many different parts of the world about their approach to living with the disease, with the goal of enabling members of the community to compare experiences and learn from each other.

EU Nurse Advisory Board: The goal of this initiative is to increase knowledge about multiple sclerosis among nurses in Europe. Genzyme is partnering with the International Organization of Multiple Sclerosis Nurses and the European Multiple Sclerosis Platform to host a nurse advisory board focused on providing more specialized education for European nurses who care for MS patients. The company has also supported work to translate multiple sclerosis nurse training modules so they may be utilized across the EU.

“I Ride with MS”: Genzyme is the lead sponsor of the “I Ride with MS” program from the National Multiple Sclerosis Society (NMSS) which creates awareness of people living with MS who ride in the NMSS’s Bike MS events around the country. The initiative was piloted last year at 15 Bike MS events, and has been expanded this year to include all 100 rides across the United States.

Swim for MS: In collaboration with the Multiple Sclerosis Association of America, Genzyme is sponsoring this campaign to raise awareness and understanding of water-based exercise programs as a wellness opportunity for the MS community. The program features personal stories from people living with MS about how water activities have impacted their lives. Swim for MS's online Aquatic Center provides print, video and web-based resources developed with the help of experts in aquatic exercise, rehabilitation therapy and MS. It also features personal stories from people with MS about how water activities have positively impacted their lives.

MSIF Grants: Genzyme has provided a communications grant to MSIF, which supports upgrades to the organization’s website, newsletters and other publications, to help ensure it is most effectively sharing information with the MS community. Genzyme has also provided a grant to support the MSIF’s World MS Day awareness activities.

Genzyme is proud to be a sponsor of World MS Day, which this year is focused on access – whether it is access to healthcare, support, work or study, there are many barriers to access that people living with MS face every day. MSIF is collecting “One Day” wishes from the community, to raise awareness about the challenges facing MS patients. Genzyme is participating in this campaign by creating “Wish Walls” at its sites globally, where employees can post their personal wishes. Visit the World MS Day website, www.worldmsday.org, to see wishes from advocates and people living with MS around the world.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.

Genzyme ® is a registered trademark of Genzyme Corporation.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,113.54 +61.81 0.36%
S&P 500 1,983.53 +9.90 0.50%
NASDAQ 4,456.0160 +31.3120 0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs